Neuraxis opened lower at $5.98, compared with its previous close of $6.03. In the last trading session, the stock traded between $5.73 and $6.22. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Neuraxis is now worth
$ 95.97
Resulting in a loss of
$ 4.03 (4.03%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.27 (-4.51%)
Day High
$6.22
Day Low
$5.73
Day Open
$5.98
Prev Close
$6.03
Volume
1,75,927
1W Return
-15.10%
1M Return
-14.70%
3M Return
-6.87%
6M Return
-29.35%
1Y Return
138.92%
Fundamentals
Market Cap ($ Mn)
82
PE Ratio
-
PB Ratio
11.11
PEG Ratio
-
ROE
-318.55%
ROCE
-271.40%
EPS (TTM)
$-0.49
Investment Returns
1 Week
-15.10%
1 Month
-14.70%
3 Months
-6.87%
6 Months
-29.35%
9 Months
23.83%
Financials
Quarterly
All values in $ Mn
0.9
Mar 25
0.9
Jun 25
0.8
Sep 25
1.0
Dec 25
1.9
Jun 26
2.0
Sep 26
Updates
9Nov
NeurAxis Q3FY26 Results: Revenue surges 150% YoY to $2.0 million
Revenue increased 150% YoY to $2.0 million driven by expanded payer coverage. Gross margin expanded 330 bps to 86.6% as unit mix shifted to full reimbursement pricing. Net loss widened to $6.5 million primarily due to $4.3 million in non-recurring stock compensation charges. Insurance coverage footprint expanded to over 147 million lives following CPT code effectiveness. Cash balance of $4.5 million supplemented by $1.7 million raised via at-the-market facility.
3 days ago
15Oct
NeurAxis secures insurance coverage for 26 million additional lives
NeurAxis secures medical policy coverage for 26 million members from a major national insurer. Total covered lives now exceed 147 million across multiple states. Coverage applies to IB-Stim, FDA-cleared for pediatric functional abdominal pain.
28 days ago
29Sep
NeurAxis appoints Craig Blanchard as chief commercial officer
Craig Blanchard appointed Chief Commercial Officer at NeurAxis on September 29, 2026. Role includes oversight of sales and marketing to support commercial expansion. Blanchard previously led commercial strategy at NICO Corporation before Stryker acquisition. Company targets broader adoption of IB-Stim amid increasing covered lives.
1mo ago
16Sep
NeurAxis to present at Lytham Partners Fall 2026 Investor Conference
NeurAxis Inc will present at the Lytham Partners Fall 2026 Investor Conference. Webcast scheduled for 11:45 am ET on September 29, 2026. Management available for virtual one-on-one investor meetings. Company focuses on FDA-cleared PENFS therapy for IBS and dyspepsia.
